Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO]

Official Title

A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer


Patients with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized to selinexor or placebo until disease progression.

Trial Description

Primary Outcome:

  • Progression Free Survival (PFS)
Secondary Outcome:
  • PFS, as assessed by a Blinded Independent Central Review (BICR), per RECIST v1.1
  • Disease specific survival (DSS)
  • Overall survival (OS)
  • Time to first subsequent treatment (TFST)
  • Progression-free survival after consecutive treatment (PFS2)
  • Time to Second Subsequent Treatment (TSST)
  • Disease Control Rate (DCR)
  • Health-Related Quality of Life (HR-QoL) as measured by EORTC QLQ30
  • Health-Related Quality of Life (HR-QoL) as measured by EORTC QLQ-EN24

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society